Intraoperative Radiation Therapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Technology (Electron IORT, and Intraoperative Brachytherapy), By Products & Service (Products, Systems/ Accelerators, Applicators & After loaders, Treatment Planning Systems, Accessories, and Services), By Application (Breast Cancer, Brain Tumour, Gastrointestinal Cancer, Head & Neck Cancer, Colorectal Cancer, Endometrial & Cervical Cancer, Lung Cancer, and Others) and Region Forecast 2020-2031

Intraoperative Radiation Therapy Market size was valued at US$ 44.7 million in 2024 and is projected to reach US$ 67.6 million by 2031, at a CAGR of 6.1% from 2025-2031. Moreover, the U.S. intraoperative radiation therapy market is projected to grow significantly, reaching an estimated value of US$ 25.2 Million by 2031. The market refers to the segment of the medical device industry focused on the development, distribution, and utilization of technologies that deliver targeted radiation during surgery. IORT involves administering a concentrated dose of radiation directly to the tumour site at the time of surgery, typically after tumour removal. This therapy is most used in the treatment of localized cancers, such as breast cancer, pancreatic cancer, and brain metastases, offering the advantage of reducing the duration of post-surgical radiation therapy.

The global IORT market is experiencing significant growth, driven by advancements in radiation therapy techniques and increasing demand for precision cancer treatments. Rising incidences of cancer, particularly breast and pancreatic cancers, have spurred interest in technologies that offer faster and more effective treatment. IORT's ability to reduce the overall treatment time and minimize damage to surrounding healthy tissue is a key factor contributing to its growing adoption. Additionally, collaborations between medical centres and technology providers are advancing research and clinical trials, further boosting market expansion. As healthcare systems focus more on personalized medicine, IORT is expected to see increasing integration into surgical oncology practices worldwide.

List Of Key Players:

The global market size is inclusive of several intraoperative radiation therapy companies such as Zeiss group, Elekta AB, ICAD Inc, Eckert & Ziegler, Isoray Inc, Becton Dickinson and Company, GMV Innovating Solutions, Sensus Healthcare Inc, Sordina IORT Technologies

Facts & Figures:

• In fact, Adoption in Breast Cancer Treatment: Major of intraoperative radiation therapy (IORT) procedures globally are performed for breast cancer management due to its effectiveness in treating early-stage and localized cancers.
• Reduction in Treatment Duration: IORT reduces traditional radiation therapy time from several weeks (typically 30–40 sessions) to a single session

List of Instances:

• In May 2019, IntraOp Medical, Inc. (US), in partnership with Massachusetts General Hospital, launched a study to evaluate the effectiveness of electron beam intraoperative radiation therapy (IORT) following chemoradiation in patients with pancreatic cancer. This study aims to explore the potential benefits of IORT as a targeted treatment approach in this challenging cancer type.

Key Developments:

• In May 2024, Ramaiah Memorial Hospital, a leading multi-super-specialty hospital in Karnataka, introduced a groundbreaking intra-operative radiation therapy (IORT) technique aimed at enhancing the quality of life for cancer patients. The hospital successfully performed two breast conservation surgeries using IORT, a method that delivers precise radiation to tumors and the tumour bed immediately after surgical resection, all in a single procedure. This innovative approach minimizes treatment duration while maintaining precision, marking a significant advancement in cancer care.
• In February 2022, Fortis Cancer Institute introduced Karnataka's first intraoperative radiotherapy (IORT) system for breast cancer treatment. This advanced system delivers a single, concentrated dose of radiation directly to the cancerous tumor site during surgery, immediately after tumor removal. IORT is primarily used for early-stage or low-risk cancer patients, significantly reducing the typical 30–40 days of radiation therapy to just 30–40 minutes. This innovation represents a major step forward in improving treatment efficiency and patient convenience.

Intraoperative Radiation Therapy Market Segmentation:

By Technology:  Electron intraoperative radiation therapy (IORT) stands as the leading technology in the market, driven by its precision and effectiveness in targeting cancerous tissues. This technology delivers a concentrated dose of electron radiation directly to the tumor site during surgery, minimizing exposure to surrounding healthy tissues. One of the key drivers behind the dominance of electron IORT is its ability to integrate seamlessly with surgical procedures, reducing the need for extended post-operative radiation sessions. This capability not only shortens the overall treatment timeline but also improves patient outcomes by addressing residual cancer cells immediately after tumor removal.

Additionally, electron IORT is highly versatile and can be applied to a variety of cancers, including breast, pancreatic, and colorectal cancers. Its precise delivery mechanism ensures minimal damage to critical organs and tissues, making it a preferred choice in cases where proximity to vital structures is a concern. Technological advancements, such as portable electron accelerators and enhanced radiation shielding, have further increased its adoption across healthcare facilities. The growing emphasis on personalized and precision medicine, coupled with increasing awareness about its clinical benefits, solidifies electron IORT's position as a leading technology in the intraoperative radiation therapy market.

By Product and Service: Systems/accelerators are leading the intraoperative radiation therapy (IORT) market, driven by their critical role in delivering precise and controlled radiation during surgical procedures. These devices are integral to the IORT process, providing high-energy electron or photon beams directly to the tumor site, ensuring targeted treatment while sparing surrounding healthy tissues. One of the primary drivers for the adoption of systems/accelerators is their ability to significantly reduce treatment times, replacing weeks of post-operative radiation therapy with a single intraoperative session. 

Advancements in accelerator technology, such as the development of portable and compact systems, have increased their usability across various surgical settings, including smaller hospitals and outpatient centres. Additionally, systems designed for versatility and compatibility with multiple surgical applications, such as breast, pancreatic, and colorectal cancers, have broadened their appeal among oncologists and surgeons. The rising demand for precision oncology, combined with a growing focus on minimizing patient discomfort and treatment durations, further boosts the adoption of these systems. As healthcare providers prioritize efficient and effective cancer care, systems/accelerators continue to be at the forefront of driving innovation and growth within the IORT market.

By Application: Breast cancer is the leading application segment in the intraoperative radiation therapy (IORT) market, driven by its high prevalence and the effectiveness of IORT in treating early-stage and localized breast cancer. The ability of IORT to deliver a concentrated dose of radiation directly to the tumor bed during surgery eliminates the need for prolonged post-operative radiation therapy, significantly reducing treatment time and improving patient convenience. This is especially advantageous for patients who may face challenges accessing daily radiotherapy sessions due to geographical or logistical constraints.

IORT also minimizes exposure to surrounding healthy tissues, such as the heart and lungs, which is critical in breast cancer treatments. This precision reduces side effects and enhances the overall quality of life for patients. Additionally, advancements in technology and the development of portable IORT systems have enabled broader adoption in surgical oncology practices worldwide. The increasing emphasis on personalized cancer treatments and the growing awareness of the benefits of IORT in breast cancer management further contribute to its leading position in the market. As breast cancer remains one of the most diagnosed cancers globally, the demand for efficient and targeted treatments like IORT is expected to continue rising.